The Paris-based company was founded in 2020 and is developing a proprietary Treg modulating drug portfolio to target immune suppressor regulatory T-cells for treating cancer and other diseases. Egle Therapeutics aims to pioneer dis-engagement of tumor-infiltrating Tregs through a unique antagonism mechanism of action using a series of IL-2 variants. Their vision is to become a game changer in the field of immunomodulating Tregs by specifically targeting the most immunosuppressive ones.